株探米国株
英語
エドガーで原本を確認する
6-K 1 tm2422540d1_6k.htm FORM 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2024

 

 

 

Commission File Number: 001-38878

 

 

 

So-Young International Inc.

 

2/F, East Tower, Poly Plaza

No. 66 Xiangbin Road

Chaoyang District, Beijing, 100012

People's Republic of China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x                                   Form 40-F ¨

 

 

 


 

Exhibit Index

 

Exhibit 99.1—Press Release

 

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

So-Young International Inc.

 

  By      

/s/ Hui Zhao

  Name : Hui Zhao
  Title : Chief Financial Officer

 

Date: August 23, 2024

 

 

 

EX-99.1 2 tm2422540d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

So-Young Reports Unaudited Second Quarter 2024 Financial Results

 

BEIJING, China, Aug. 23, 2024 — So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the second quarter ended June 30, 2024.

 

Second Quarter 2024 Financial Highlights

 

· Total revenues were RMB407.4 million (US$56.1 million1), compared with RMB412.1 million in the corresponding period of 2023, exceeding the high end of guidance.

 

· Net income attributable to So-Young International Inc. was RMB18.9 million (US$2.6 million), compared with net loss attributable to So-Young International Inc. of RMB2.6 million in the same period of 2023.

 

· Non-GAAP net income attributable to So-Young International Inc.2 was RMB22.2 million (US$3.1 million), compared with non-GAAP net income attributable to So-Young International Inc. of RMB15.5 million in the same period of 2023.

 

Second Quarter 2024 Operational Highlights

 

· Average mobile MAUs were 1.5 million, compared with 3.0 million in the second quarter of 2023.

 

· Number of medical service providers subscribing to information services on So-Young’s platform was 1,174, compared with 1,659 in the second quarter of 2023.

 

· Total number of purchasing users through reservation services was 137.5 thousand and the aggregate value of medical aesthetic treatment transactions facilitated by So-Young’s platform was RMB427.8 million.

 

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, “Our performance during the second quarter was solid with total revenue beating guidance on the back of a significant 22.6% year-over-year increase in sales of medical products and maintenance services. This solid performance is directly attributable to our strategic initiatives and ability to capitalize on industry trends and enhance the overall vertical integration and diversification of our business. We made significant progress in expanding our chain of clinics, opening 14 in prime commercial areas across eight core cities. Notably, our Beijing clinic continues to lead the industry in key operating metrics, including repeat customer rates and customer acquisition costs. We plan to swiftly replicate this proven model in other cities to further expand our offline footprint. Leveraging the reputational strength of our brand and extensive consumer behavior data, we have built a solid foundation to drive upstream product development and customization. Product sales continue to grow rapidly with a strong and diversified pipeline currently in development with our partners. Moving forward, we will continue to explore opportunities across the upstream, midstream and downstream sectors, solve industry pain points, and lead the industry towards a new era of quality medical aesthetics.”

 

 

1 This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB7.2672 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on June 28, 2024.

2 Non-GAAP net income/(loss) attributable to So-Young International Inc. is defined as net income/(loss) attributable to So-Young International Inc. excluding share-based compensation expenses attributable to So-Young International Inc. See “Reconciliation of GAAP and Non-GAAP Results” at the end of this press release.

 

1


 

Mr. Hui Zhao, Chief Financial Officer of So-Young, added, “Growth during the quarter was fueled by the progress we made in integrating our platform across the medical aesthetic value chain. This not only promotes the high-quality and sustainable development of the industry, but also further strengthens our market position. As we accelerate the development of our new businesses, we will continue to prudently manage costs and enhance operational efficiency. We are confident that these strategic initiatives will continue to drive sustainable growth and enhance shareholder value over the long-term.”

 

Second Quarter 2024 Financial Results

 

Revenues

 

Total revenues were RMB407.4 million (US$56.1 million), a decrease of 1.1% from RMB412.1 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young’s platform.

 

· Information services and other revenues were RMB279.2 million (US$38.4 million), a decrease of 6.6% from RMB298.9 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young’s platform.

 

· Reservation services revenues were RMB22.4 million (US$3.1 million), a decrease of 16.9% from RMB26.9 million in the same period of 2023. The decrease was primarily due to the policy change for commission rates and subsidies.

 

· Sales of medical products and maintenance services were RMB105.8 million (US$14.6 million), an increase of 22.6% from RMB86.3 million in the same period of 2023, primarily due to an increase in the order volumes for cosmetic products.

 

Cost of Revenues

 

Cost of revenues was RMB155.1 million (US$21.3 million), an increase of 3.1% from RMB150.4 million in the second quarter of 2023. The increase was primarily due to an increase in costs associated with sales of cosmetic products. Cost of revenues included share-based compensation expenses of RMB0.2 million (US$0.0 million), compared with the share-based compensation expenses of RMB0.4 million in the corresponding period of 2023.

 

· Cost of services and others were RMB101.9 million (US$14.0 million), a decrease of 4.4% from RMB106.5 million in the second quarter of 2023. The decrease was primarily due to a decrease in the cost of services associated with So-Young Prime.

 

· Cost of medical products sold and maintenance services were RMB53.2 million (US$7.3 million), an increase of 21.3% from RMB43.9 million in the second quarter of 2023. The increase was primarily due to an increase in costs associated with the sales of cosmetic products.

 

Operating Expenses

 

Total operating expenses were RMB245.6 million (US$33.8 million), a decrease of 13.0% from RMB282.4 million in the second quarter of 2023.

 

· Sales and marketing expenses were RMB132.3 million (US$18.2 million), a decrease of 4.1% from RMB137.9 million in the second quarter of 2023. The decrease was mainly due to a decrease in expenses associated with branding and user acquisition activities. Sales and marketing expenses included share-based compensation expenses of RMB0.2 million (US$0.0 million), compared with RMB0.8 million in the corresponding period of 2023.

 

· General and administrative expenses were RMB70.8 million (US$9.7 million), a decrease of 23.3% from RMB92.3 million in the second quarter of 2023. The decrease was primarily due to decreases in share-based compensation expenses and professional consulting fees. General and administrative expenses included share-based compensation expenses of RMB2.0 million (US$0.3 million), compared with RMB15.5 million in the corresponding period of 2023. The decrease in share-based compensation expenses was due to the compensation costs of the restricted share units granted in 2023, which were fully recognized by the end of the first quarter of 2024.

 

2


 

· Research and development expenses were RMB42.5 million (US$5.8 million), a decrease of 18.5% from RMB52.1 million in the second quarter of 2023. The decrease was primarily attributable to improvements in staff efficiency. Research and development expenses included share-based compensation expenses of RMB0.8 million (US$0.1 million), compared with RMB1.3 million in the corresponding period of 2023.

 

Income Tax Benefits

 

Income tax benefits were RMB2.6 million (US$0.4 million), compared with income tax benefits of RMB0.8 million in the same period of 2023.

 

Net Income/(Loss) Attributable to So-Young International Inc.

 

Net income attributable to So-Young International Inc. was RMB18.9 million (US$2.6 million), compared with a net loss attributable to So-Young International Inc. of RMB2.6 million in the second quarter of 2023.

 

Non-GAAP Net Income Attributable to So-Young International Inc.

 

Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses attributable to So-Young International Inc., was RMB22.2 million (US$3.1 million), compared with RMB15.5 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2023.

 

Basic and Diluted Earnings/(Loss) per ADS

 

Basic and diluted earnings per ADS attributable to ordinary shareholders were RMB0.18 (US$0.02) and RMB0.18 (US$0.02), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB0.02 and RMB0.02, respectively, in the same period of 2023.

 

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

 

As of June 30, 2024, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,245.1 million (US$171.3 million), compared with RMB1,341.6 million as of December 31, 2023.

 

Business Outlook

 

For the third quarter of 2024, So-Young expects total revenues to be between RMB350.0 million (US$48.2 million) and RMB370.0 million (US$50.9 million), representing a 9.2% to 4.0% decrease from the same period in 2023. The above outlook is based on the current market conditions and reflects the Company’s preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.

 

Non-GAAP Financial Measures

 

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income/(loss) attributable to So-Young International Inc. by excluding share-based compensation expenses from income/(loss) from operations and net income/(loss) attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company’s operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company’s core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company’s results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company’s performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

 

3


 

Conference Call Information

 

So-Young's management will hold an earnings conference call on Friday, August 23, 2024, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

 

International: +1-412-902-4272
Mainland China: 4001-201203
US: +1-888-346-8982
Hong Kong: +852-301-84992
Passcode: So-Young International Inc.

 

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, August 30, 2024. The dial-in details are:

 

International: +1-412-317-0088
US: +1-877-344-7529
Passcode: 3725692

 

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

 

About So-Young International Inc.

 

So-Young International Inc. (Nasdaq: SY) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young’s strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.

 

Safe Harbor Statement

 

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young’s strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young’s strategies; So-Young’s future business development, financial condition and results of operations; So-Young’s ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young’s revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

 

4


 

For more information, please contact:

 

So-Young

 

Investor Relations

Ms. Mona Qiao

Phone: +86-10-8790-2012

E-mail: ir@soyoung.com

 

Christensen

 

In China

Ms. Dee Wang

Phone: +86-10-5900-1548

E-mail: dee.wang@christensencomms.com

 

In US

Ms. Linda Bergkamp

Phone: +1-480-614-3004

Email: linda.bergkamp@christensencomms.com

 

5


 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except for share and per share data)

 

    As of  
    December 31,     June 30,     June 30,  
    2023     2024     2024  
    RMB     RMB     US$  
Assets                  
Current assets:                        
Cash and cash equivalents     426,119       456,927       62,875  
Restricted cash and term deposits     14,695       83,224       11,452  
Trade receivables     57,219       81,585       11,226  
Inventories     118,924       143,374       19,729  
Receivables from online payment platforms     23,158       20,819       2,865  
Amounts due from related parties     9,212       10,292       1,416  
Term deposits and short-term investments     900,823       704,979       97,008  
Prepayment and other current assets     171,774       237,267       32,649  
Total current assets     1,721,924       1,738,467       239,220  
Non-current assets:                        
Long-term investments     261,016       278,546       38,329  
Intangible assets     145,253       133,104       18,316  
Goodwill     540,693       540,693       74,402  
Property and equipment, net     116,782       137,162       18,874  
Deferred tax assets     78,034       80,626       11,095  
Operating lease right-of-use assets     118,408       139,885       19,249  
Other non-current assets     232,455       183,546       25,257  
Total non-current assets     1,492,641       1,493,562       205,522  
Total assets     3,214,565       3,232,029       444,742  
                         
Liabilities                        
Current liabilities:                        
Short-term borrowings     29,825       39,713       5,465  
Taxes payable     56,894       57,567       7,921  
Contract liabilities     103,374       95,656       13,163  
Salary and welfare payables     86,290       79,716       10,969  
Amounts due to related parties     388       138       19  
Accrued expenses and other current liabilities     233,913       249,175       34,287  
Operating lease liabilities-current     29,739       27,482       3,782  
Total current liabilities     540,423       549,447       75,606  
Non-current liabilities:                        
Operating lease liabilities-non current     86,210       114,478       15,753  
Deferred tax liabilities     25,082       21,342       2,937  
Other non-current liabilities     1,536       1,610       222  
Total non-current liabilities     112,828       137,430       18,912  
Total liabilities     653,251       686,877       94,518  

 

6


 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Continued)

(Amounts in thousands, except for share and per share data)

 

Shareholders’ equity:                  
Treasury stock     (358,453 )     (365,451 )     (50,288 )
Class A ordinary shares (US$0.0005 par value; 750,000,000 shares authorized as of December 31, 2023 and June 30, 2024; 73,688,044 and 63,422,436 shares issued and outstanding as of December 31, 2023, 77,387,894 and  66,469,129 shares issued and outstanding as of June 30, 2024, respectively)     238       251       35  
Class B ordinary shares (US$ 0.0005 par value; 20,000,000 shares authorized as of December 31, 2023 and June 30, 2024; 12,000,000 shares issued and outstanding as of December 31, 2023 and June 30, 2024)     37       37       5  
Additional paid-in capital     3,080,433       3,065,650       421,847  
Statutory reserves     33,855       33,855       4,659  
Accumulated deficit     (330,166 )     (332,465 )     (45,749 )
Accumulated other comprehensive income     18,185       23,934       3,293  
Total So-Young International Inc. shareholders’ equity     2,444,129       2,425,811       333,802  
Non-controlling interests     117,185       119,341       16,422  
Total shareholders’ equity     2,561,314       2,545,152       350,224  
Total liabilities and shareholders’ equity     3,214,565       3,232,029       444,742  

 

7


 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except for share and per share data)

 

    For the Three Months Ended     For the Six Months Ended  
    June 30,
2023
    June 30,
2024
    June 30,
2024
    June 30,
2023
    June 30,
2024
    June 30,
2024
 
    RMB     RMB     US$     RMB     RMB     US$  
Revenues:                                                
Information services and others     298,879       279,216       38,421       509,163       487,964       67,146  
Reservation services     26,903       22,356       3,076       56,584       45,420       6,250  
Sales of medical products and maintenance services     86,284       105,808       14,560       156,422       192,278       26,458  
Total revenues     412,066       407,380       56,057       722,169       725,662       99,854  
Cost of revenues:                                                
Cost of services and others     (106,519 )     (101,853 )     (14,015 )     (188,019 )     (176,075 )     (24,229 )
Cost of medical products sold and maintenance services     (43,859 )     (53,198 )     (7,320 )     (76,080 )     (96,291 )     (13,250 )
Total cost of revenues     (150,378 )     (155,051 )     (21,335 )     (264,099 )     (272,366 )     (37,479 )
Gross profit     261,688       252,329       34,722       458,070       453,296       62,375  
Operating expenses:                                                
Sales and marketing expenses     (137,921 )     (132,308 )     (18,206 )     (250,432 )     (245,564 )     (33,791 )
General and administrative expenses     (92,341 )     (70,799 )     (9,742 )     (153,855 )     (155,752 )     (21,432 )
Research and development expenses     (52,141 )     (42,498 )     (5,848 )     (107,934 )     (82,089 )     (11,296 )
Total operating expenses     (282,403 )     (245,605 )     (33,796 )     (512,221 )     (483,405 )     (66,519 )
(Loss)/Income from operations     (20,715 )     6,724       926       (54,151 )     (30,109 )     (4,144 )
Other income/(expenses):                                                
Investment income, net     3,370       788       108       10,222       2,887       397  
Interest income, net     13,966       11,718       1,612       25,893       24,031       3,307  
Exchange (losses)/gains     (1,579 )     16       2       (1,154 )     410       56  
Share of losses of equity method investee     (3,699 )     (3,733 )     (514 )     (6,870 )     (7,729 )     (1,064 )
Others, net     6,562       2,039       281       8,587       5,319       732  
(Loss)/Income before tax     (2,095 )     17,552       2,415       (17,473 )     (5,191 )     (716 )
Income tax benefits     785       2,571       354       5,049       5,128       706  
Net (loss)/income     (1,310 )     20,123       2,769       (12,424 )     (63 )     (10 )
Net income attributable to noncontrolling interests     (1,268 )     (1,182 )     (163 )     (2,102 )     (2,236 )     (308 )
Net (loss)/income attributable to So-Young International Inc.     (2,578 )     18,941       2,606       (14,526 )     (2,299 )     (318 )

 

8


 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued)

(Amounts in thousands, except for share and per share data)

 

    For the Three Months Ended     For the Six Months Ended  
    June 30,
2023
    June 30,
2024
    June 30,
2024
    June 30,
2023
    June 30,
2024
    June 30,
2024
 
    RMB     RMB     US$     RMB     RMB     US$  
Net (loss)/earnings per ordinary share                                                
Net (loss)/earnings per ordinary share attributable to ordinary shareholder - basic     (0.03 )     0.24       0.03       (0.18 )     (0.03 )     (0.00 )
Net (loss)/earnings per ordinary share attributable to ordinary shareholder - diluted     (0.03 )     0.24       0.03       (0.18 )     (0.03 )     (0.00 )
Net (loss)/earnings per ADS attributable to ordinary shareholders - basic (13 ADS represents 10 Class A ordinary shares)     (0.02 )     0.18       0.02       (0.14 )     (0.02 )     (0.00 )
Net (loss)/earnings per ADS attributable to ordinary shareholders - diluted (13 ADS represents 10 Class A ordinary shares)     (0.02 )     0.18       0.02       (0.14 )     (0.02 )     (0.00 )
Weighted average number of ordinary shares used in computing earnings/(loss) per share, basic*     77,310,426       79,586,926       79,586,926       78,580,369       79,569,190       79,569,190  
Weighted average number of ordinary shares used in computing earnings/(loss) per share, diluted*     77,310,426       79,899,412       79,899,412       78,580,369       79,569,190       79,569,190  
                                                 
Share-based compensation expenses included in:                                                
Cost of services and others     (412 )     (229 )     (32 )     (1,217 )     (174 )     (24 )
Sales and marketing expenses     (823 )     (184 )     (25 )     (2,317 )     (237 )     (33 )
General and administrative expenses     (15,546 )     (2,015 )     (277 )     (21,564 )     (26,468 )     (3,642 )
Research and development expenses     (1,305 )     (817 )     (112 )     (2,182 )     (1,660 )     (228 )

 

* Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.

 

9


 

SO-YOUNG INTERNATIONAL INC.

Reconciliation of GAAP and Non-GAAP Results

(Amounts in thousands, except for share and per share data)

 

    For the Three Months Ended     For the Six Months Ended  
   

June 30,

2023

   

June 30,

2024

    June 30,
2024
    June 30,
2023
    June 30,
2024
    June 30,
2024
 
    RMB     RMB     US$     RMB     RMB     US$  
GAAP (loss)/income from operations     (20,715 )     6,724       926       (54,151 )     (30,109 )     (4,144 )
Add back: Share-based compensation expenses     18,086       3,245       446       27,280       28,539       3,927  
Non-GAAP (loss)/income from operations     (2,629 )     9,969       1,372       (26,871 )     (1,570 )     (217 )
                                                 
GAAP net (loss)/income attributable to So-Young International Inc.     (2,578 )     18,941       2,606       (14,526 )     (2,299 )     (318 )
Add back: Share-based compensation expenses     18,086       3,245       446       27,280       28,539       3,927  
Non-GAAP net income attributable to So-Young International Inc.     15,508       22,186       3,052       12,754       26,240       3,609  

 

10